Skip to main content
SpringerLink
Log in

Immunonkologie bei Brustkrebs

Immunotherapy in breast cancer

  • Gynäkologie aktuell
  • Published:
Der Gynäkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70

    Article  CAS  PubMed  Google Scholar 

  2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

    Article  CAS  PubMed  Google Scholar 

  3. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073–1081

    Article  CAS  PubMed  Google Scholar 

  4. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL (2011) 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 60(3):319–326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ehrlich P (1909) Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd 5:273–290

    Google Scholar 

  6. Wiemann B, Starnes CO (1994) Coley’s toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 64:529–564

    Article  CAS  PubMed  Google Scholar 

  7. Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immuno-editing and ist three component phases – elemination equilibrium and escape. Curr Opin Immunol 27:16–25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Li X, Lu P, Li B, Zhang W, Yang R, Chu Y, Luo K (2017) Interleukin 2 and interleukin 10 function synergistically to promote CD8+ T cell cytotoxicity, which is suppressed by regulatory T cells in breast cancer. Int J Biochem Cell Biol 6(87):1–7

    Article  CAS  Google Scholar 

  9. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Lee RS, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214–218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hartkopf AD, Taran FA, Wallwiener M, Walter CB, Krämer B, Grischke EM, Brucker SY (2016) PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer. Breast Care (Basel) 11(6):385–390

    Article  Google Scholar 

  11. Schmidt HH, Ge Y, Hartmann FJ, Conrad H, Klug F, Nittel S, Bernhard H, Domschke C, Schuetz F, Sohn C, Beckhove P (2013) HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T‑cell responses in breast carcinoma patients. Oncoimmunology 2(6):e24962

    Article  PubMed  PubMed Central  Google Scholar 

  12. Cohen EP, Kim TS (1994) Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin Cancer Biol 5:419–428

    PubMed  Google Scholar 

  13. Coulie PG et al (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92:7976–7980

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Black PH (1980) Shedding from the cell surface of normal and cancer cells. Adv Cancer Res 32:75–199

    Article  CAS  PubMed  Google Scholar 

  15. Ueno T, Toi M, Tominaga T (1999) Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 5(11):3529–3533

    CAS  PubMed  Google Scholar 

  16. Heppner IB, Untch M, Denkert C, Pfitzner BM, Lederer B, Schmitt W, Eidtmann H, Fasching PA, Tesch H, Solbach C, Rezai M, Zahm DM, Holms F, Glados M, Krabisch P, Heck E, Ober A, Lorenz P, Diebold K, Habeck JO, Loibl S (2016) Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer. Clin Cancer Res 22(23):5747–5754

    Article  Google Scholar 

  17. Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer JU, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S (2015) Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2‑positive and triple-negative primary breast cancers. J Clin Oncol 33(9):983–991

    Article  CAS  PubMed  Google Scholar 

  18. Jiang D, Gao Z, Cai Z, Wang M, He J (2015) Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer 15:727. doi:10.1186/s12885-015-1742-7

    Article  PubMed  PubMed Central  Google Scholar 

  19. Shi Y, Fan X, Deng H, Brezski RJ, Rycyzyn M, Jordan RE, Strohl WR, Zou Q, Zhang N, An Z (2015) Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages. J Immunol 194(9):4379–4386

    Article  CAS  PubMed  Google Scholar 

  20. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006–2017. doi:10.1056/NEJMoa1414428

    Article  PubMed  Google Scholar 

  21. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540–1550

    Article  CAS  PubMed  Google Scholar 

  22. Clifton GT, Gall V, Peoples GE, Mittendorf EA (2016) Clinical development of the E75 vaccine in breast cancer. Breast Care (Basel) 11(2):116–121

    Article  Google Scholar 

  23. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, Gates JD, Sears AK, Stojadinovic A, Ponniah S, Peoples GE (2012) Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I‑01 and I‑02. Cancer 118(10):2594–2602

    Article  CAS  PubMed  Google Scholar 

  24. Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE (2014) Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 25(9):1735–1742

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Travis Clifton G, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EA (2017) Results of a phase Ib trial of combination immunotherapy with a CD8+ T cell eliciting vaccine and Trastuzumab in breast cancer patients. Ann Surg Oncol. doi:10.1245/s10434-017-5844-0

    PubMed  Google Scholar 

  26. Svane IM, Pedersen AE, Nikolajsen K, Zocca MB (2008) Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine 26(36):4716–4724

    Article  CAS  PubMed  Google Scholar 

  27. Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong ML, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, Rosenberg SA (2016) Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol 34(20):2389–2397

    Article  PubMed  Google Scholar 

  28. Domschke C, Ge Y, Bernhardt I, Schott S, Keim S, Juenger S, Bucur M, Mayer L, Blumenstein M, Rom J, Heil J, Sohn C, Schneeweiss A, Beckhove P, Schuetz F (2013) Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. Cancer Immunol Immunother 62(6):1053–1060

    Article  CAS  PubMed  Google Scholar 

  29. Schuetz F, Ehlert K, Specht S, Schneeweis A, Rom J, Sohn C, Schirrmacher V, Beckhove P (2008) First Phase I clinical study of adoptive cellular cancer immunotherapy with autologous bone-marrow derived tumor antigen reactive memory T cells: feasibility, toxicity and immunological effects. Canc Immunol Immunother 58(6):887–900

    Article  Google Scholar 

  30. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA (2011) Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17(19):6287–6289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Assadipour Y, Zacharakis N, Crystal JS, Prickett TD, Gartner JJ, Somerville RP, Xu H, Black MA, Jia L, Chinnasamy H, Kriley I, Lu L, Wunderlich JR, Zheng Z, Lu YC, Robbins PF, Rosenberg SA, Goff SL, Feldman SA (2017) Characterization of an immunogenic mutation in a patient with metastatic triple negative breast cancer. Clin Cancer Res. doi:10.1158/1078-0432.ccr-16-1423

    PubMed  Google Scholar 

  32. Reilley MJ, Bailey A, Subbiah V, Janku F, Naing A, Falchook G, Karp D, Piha-Paul S, Tsimberidou A, Fu S, Lim J, Bean S, Bass A, Montez S, Vence L, Sharma P, Allison J, Meric-Bernstam F, Hong DS (2017) Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35. doi:10.1186/s40425-017-0238-1

    Article  PubMed  PubMed Central  Google Scholar 

  33. Sage PT et al (2013) The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol 14(2):152–161

    Article  CAS  PubMed  Google Scholar 

  34. Postow MA, Callahan MK, Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33(17):1974–1982

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, Karantza V, Buisseret L (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 34(21):2460–2467

    Article  CAS  PubMed  Google Scholar 

  36. Kefford R, Topalian SL, ASCO 2014 et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030

    Article  Google Scholar 

  37. Gibson J (2015) Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol 16(6):e264

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik Heidelberg, Im Neuenheimer Feld 440, 69120, Heidelberg, Deutschland

    Florian Schütz, Stefan Stefanovic, Christof Sohn, Alexandra von Au, Luisa Mayer & Christoph Domschke

Authors
  1. Florian Schütz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Stefanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christof Sohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexandra von Au
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luisa Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christoph Domschke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florian Schütz.

Ethics declarations

Interessenkonflikt

F. Schütz, S. Stefanovic, C. Sohn, A. von Au, L. Mayer und C. Domschke geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Redaktion

T. Fehm, Düsseldorf

W. Janni, Ulm

R. Kimmig, Essen

N. Maass, Kiel

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schütz, F., Stefanovic, S., Sohn, C. et al. Immunonkologie bei Brustkrebs. Gynäkologe 50, 546–550 (2017). https://doi.org/10.1007/s00129-017-4094-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-017-4094-3

Search

Navigation